Applied Molecular Transport logo
Applied Molecular Transport AMTI
report update icon

Quarterly report 2023-Q3
added 06-13-2026

Applied Molecular Transport Financial Ratios 2022-2011 | AMTI

Annual Financial Ratios Applied Molecular Transport

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-0.2 -2.5 -16.8 - - - - - - - - -

EPS

-3.2 -2.7 -2.9 -3.8 - - - - - - - -

EV (Enterprise Value)

7.6 M 138 M 1.12 B -8.11 M 47.1 M - - - - - - -

EBITDA per Share

-3.2 -2.59 -2.83 -3.75 - - - - - - - -

EV/EBITDA

-0.1 -1.4 -17.3 0.3 - - - - - - - -

PEG

- - 0.13 - - - - - - - - -

P/B

0.4 1.5 8.5 - - - - - - - - -

P/CF

-0.2 -3.0 -19.0 - - - - - - - - -

ROE %

-207.64 -61.30 -50.55 39.11 - - - - - - - -

ROA %

-117.57 -46.85 -47.48 -72.78 - - - - - - - -

ROCE %

-209.11 -61.61 -50.64 -82.01 - - - - - - - -

Current Ratio

2.3 4.2 16.5 8.3 - - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Applied Molecular Transport

2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.17 -0.44 -0.71 - -0.65 -0.93 -1.1 - -0.68 -0.62 -0.58 - -0.48 -1.11 -2.06 - -1.07 -0.99 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

-0.16 -0.43 -0.71 - -0.59 -0.88 -1.08 - -0.61 -0.58 -0.56 - -0.47 -1.08 -2.05 - -1.05 -0.99 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

-236.06 -230.12 -179.46 -102.23 -116.09 -95.29 -76.54 -43.24 -54.49 -49.95 -50.22 -32.20 -21.23 0.22 19.72 31.35 10.97 10.19 10.19 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

-157.85 -147.60 -101.59 -68.07 -80.62 -70.93 -62.71 -39.28 -49.92 -46.27 -46.66 -30.47 -50.88 -59.21 -10.92 - -20.41 -18.97 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

-241.69 -234.10 -181.52 -102.71 -116.57 -95.37 -76.55 -43.25 -54.53 -49.95 -50.32 -32.28 -21.27 0.28 -11.73 - 11.02 10.27 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

5.3 5.8 1.8 2.3 2.7 3.0 3.4 4.2 10.6 13.9 9.8 16.5 18.3 22.9 16.5 8.3 8.3 8.3 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Applied Molecular Transport, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Kamada Ltd. Kamada Ltd.
KMDA
$ 8.46 0.87 % $ 488 M israelIsrael
Kiniksa Pharmaceuticals, Ltd. Kiniksa Pharmaceuticals, Ltd.
KNSA
$ 74.61 0.03 % $ 5.54 B usaUSA
Kodiak Sciences Kodiak Sciences
KOD
$ 94.8 4.04 % $ 5.04 B usaUSA
Karyopharm Therapeutics Karyopharm Therapeutics
KPTI
$ 1.22 1.24 % $ 13.3 K usaUSA
Keros Therapeutics Keros Therapeutics
KROS
$ 11.4 1.88 % $ 424 M usaUSA
Krystal Biotech Krystal Biotech
KRYS
$ 332.56 0.12 % $ 9.63 B usaUSA
Kura Oncology Kura Oncology
KURA
$ 10.71 1.3 % $ 939 M usaUSA
Kymera Therapeutics Kymera Therapeutics
KYMR
$ 111.79 1.16 % $ 9.45 B usaUSA
Kazia Therapeutics Limited Kazia Therapeutics Limited
KZIA
$ 9.6 1.56 % $ 146 M australiaAustralia
Lineage Cell Therapeutics Lineage Cell Therapeutics
LCTX
$ 0.96 0.1 % $ 221 M usaUSA
Legend Biotech Corporation Legend Biotech Corporation
LEGN
$ 19.89 5.69 % $ 7.33 B usaUSA
MediWound Ltd. MediWound Ltd.
MDWD
$ 13.77 0.25 % $ 375 M israelIsrael
Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Incorporated
LGND
$ 312.37 0.65 % $ 6.04 B usaUSA
Longeveron Longeveron
LGVN
$ 2.69 0.74 % $ 47.3 B usaUSA
Eli Lilly and Company Eli Lilly and Company
LLY
$ 1 157.08 0.27 % $ 1.04 T usaUSA
Lipocine Lipocine
LPCN
$ 2.2 1.85 % $ 12 M usaUSA
Liquidia Corporation Liquidia Corporation
LQDA
$ 30.26 0.58 % $ 2.6 B usaUSA
Larimar Therapeutics Larimar Therapeutics
LRMR
$ 3.2 1.75 % $ 266 M usaUSA
Lantern Pharma Lantern Pharma
LTRN
$ 1.01 0.92 % $ 11 M usaUSA
Lexicon Pharmaceuticals Lexicon Pharmaceuticals
LXRX
$ 1.88 0.53 % $ 683 M usaUSA
Mustang Bio Mustang Bio
MBIO
$ 0.46 0.02 % $ 2.26 M usaUSA
Moleculin Biotech Moleculin Biotech
MBRX
$ 0.5 1.84 % $ 592 K usaUSA
Seres Therapeutics Seres Therapeutics
MCRB
$ 3.35 0.85 % $ 29.7 M usaUSA
Madrigal Pharmaceuticals Madrigal Pharmaceuticals
MDGL
$ 503.96 0.31 % $ 11.3 B usaUSA
Mesoblast Limited Mesoblast Limited
MESO
$ 14.65 2.55 % $ 17.7 B australiaAustralia
MacroGenics MacroGenics
MGNX
$ 3.86 2.39 % $ 244 M usaUSA
Mirum Pharmaceuticals Mirum Pharmaceuticals
MIRM
$ 85.48 0.46 % $ 4.29 B usaUSA
Milestone Pharmaceuticals Milestone Pharmaceuticals
MIST
$ 0.87 5.57 % $ 92.4 M canadaCanada
MannKind Corporation MannKind Corporation
MNKD
$ 3.9 16.77 % $ 1.19 B usaUSA
MediciNova MediciNova
MNOV
$ 1.68 0.52 % $ 82.4 M usaUSA
Monopar Therapeutics Monopar Therapeutics
MNPR
$ 79.67 0.17 % $ 590 M usaUSA
Mereo BioPharma Group plc Mereo BioPharma Group plc
MREO
$ 0.4 7.72 % $ 319 M britainBritain
Merck & Co. Merck & Co.
MRK
$ 145.31 0.4 % $ 364 B usaUSA
Marker Therapeutics Marker Therapeutics
MRKR
$ 1.07 2.36 % $ 16.4 M usaUSA
Moderna Moderna
MRNA
$ 192.57 3.13 % $ 74.9 B usaUSA
Maravai LifeSciences Holdings Maravai LifeSciences Holdings
MRVI
$ 7.66 0.13 % $ 1.11 B usaUSA
Matinas BioPharma Holdings Matinas BioPharma Holdings
MTNB
$ 2.55 2.13 % $ 14 M usaUSA
Neurocrine Biosciences Neurocrine Biosciences
NBIX
$ 141.84 2.52 % $ 14.1 B usaUSA
Nanobiotix S.A. Nanobiotix S.A.
NBTX
$ 31.16 0.48 % $ 1.49 T franceFrance
NuCana plc NuCana plc
NCNA
$ 1.35 11.57 % $ 15.2 B britainBritain
Minerva Neurosciences Minerva Neurosciences
NERV
$ 3.35 0.6 % $ 28.4 M usaUSA
Nektar Therapeutics Nektar Therapeutics
NKTR
$ 60.55 2.2 % $ 1.02 B usaUSA
Nkarta Nkarta
NKTX
$ 2.62 0.19 % $ 194 M usaUSA
NanoViricides NanoViricides
NNVC
$ 1.3 0.78 % $ 26.2 M usaUSA
Nurix Therapeutics Nurix Therapeutics
NRIX
$ 23.71 0.15 % $ 2.05 B usaUSA
Intellia Therapeutics Intellia Therapeutics
NTLA
$ 12.06 0.25 % $ 1.31 B usaUSA
Nuvation Bio Nuvation Bio
NUVB
$ 5.6 1.07 % $ 1.91 B usaUSA
Novavax Novavax
NVAX
$ 10.81 0.18 % $ 1.75 B usaUSA
Novo Nordisk A/S Novo Nordisk A/S
NVO
$ 37.91 0.05 % $ 168 B danmarkDanmark
Novartis AG Novartis AG
NVS
$ 142.57 0.98 % $ 276 B schweizSchweiz